StockNews.AI
EXEL
StockNews.AI
2 days

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

1. Exelixis authorized an additional $500M stock repurchase program before December 2025. 2. Current $500M repurchase to complete by Q2 2025; further repurchases planned.

2 mins saved
Full Article

FAQ

Why Bullish?

The buyback signals management confidence and reduces outstanding shares, often supporting EPS. Historical biotech buybacks have correlated with short-term price increases.

How important is it?

A $500M+ buyback is a significant capital allocation, directly influencing share value and investor confidence.

Why Short Term?

Repurchase programs generally boost investor sentiment immediately and can elevate stock prices in the near term.

Related Companies

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company's Board of Directors has authorized the repurchase of up to an additional $500 million of the company's common stock before December 31, 2025. Exelixis plans on completing the currently ongoing $500 million stock repurchase program (SRP), announced in August 2024, in the second quarter of 2025, and commence stock repurchases under the newly authorized SRP thereafter. The February 2025 SRP is the fou.

Related News